Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.
1/5 보강
[BACKGROUND AND AIMS] Anti-PD-1/PD-L1 immunotherapy has changed the treatment landscape of lung cancer.
APA
Mohiuddin M (2026). Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.. Health science reports, 9(1), e71749. https://doi.org/10.1002/hsr2.71749
MLA
Mohiuddin M. "Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.." Health science reports, vol. 9, no. 1, 2026, pp. e71749.
PMID
41523849
Abstract
[BACKGROUND AND AIMS] Anti-PD-1/PD-L1 immunotherapy has changed the treatment landscape of lung cancer. This new approach provides the ability to revitalize the immune system to specifically target and kill cancer cells, thereby creating a new treatment paradigm for patients with non-small cell lung cancer (NSCLC).
[METHODS] In this study, relevant information was extracted from published articles available on PubMed, Scopus, and Google Scholar. The keywords "PD-1", "PD-L1", "Immunotherapy", and "NSCLC" were used to search for relevant information.
[RESULTS] Despite the promise of durable responses to treatment and overall survival benefits, there are many challenges related to anti-PD-1/PD-L1 therapies, including immune escape, patient heterogeneity, and immune-related side effects. In this study, we discuss the rationale for targeting the PD-1/PD-L1 axis, the complex mechanism of immune activation and resistance, innovative ideas, and future directions for the field to enhance anti-PD-1/PD-L1 outcomes.
[CONCLUSION] Investigating resistance mechanisms and developing innovative treatment strategies are essential to optimize the clinical benefits of PD-1/PD-L1 immunotherapy for NSCLC.
[METHODS] In this study, relevant information was extracted from published articles available on PubMed, Scopus, and Google Scholar. The keywords "PD-1", "PD-L1", "Immunotherapy", and "NSCLC" were used to search for relevant information.
[RESULTS] Despite the promise of durable responses to treatment and overall survival benefits, there are many challenges related to anti-PD-1/PD-L1 therapies, including immune escape, patient heterogeneity, and immune-related side effects. In this study, we discuss the rationale for targeting the PD-1/PD-L1 axis, the complex mechanism of immune activation and resistance, innovative ideas, and future directions for the field to enhance anti-PD-1/PD-L1 outcomes.
[CONCLUSION] Investigating resistance mechanisms and developing innovative treatment strategies are essential to optimize the clinical benefits of PD-1/PD-L1 immunotherapy for NSCLC.